PHARMACOSMOS A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 2.3% 0.4% 0.7%  
Credit score (0-100)  0 0 63 99 94  
Credit rating  N/A N/A BBB AAA AA  
Credit limit (mDKK)  102.8 86.9 0.0 132.0 206.9  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4

Net sales  609 782 877 1,104 1,613  
Gross profit  329 465 545 701 1,245  
EBITDA  128 219 211 272 680  
EBIT  128 219 211 272 680  
Pre-tax profit (PTP)  59.6 -118.5 170.0 165.9 1,038.9  
Net earnings  59.6 -118.5 170.0 114.3 789.7  
Pre-tax profit without non-rec. items  128 219 211 161 798  

 
See the entire income statement

Balance sheet (mDKK) 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4

Tangible assets total  0.0 0.0 0.0 4.4 6.7  
Shareholders equity total  894 671 807 855 1,636  
Interest-bearing liabilities  0.0 0.0 0.0 759 883  
Balance sheet total (assets)  1,355 1,479 1,590 1,753 2,658  

Net Debt  0.0 0.0 0.0 96.9 -168  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4

Net sales  609 782 877 1,104 1,613  
Net sales growth  6.3% 28.4% 12.1% 25.9% 46.1%  
Gross profit  329 465 545 701 1,245  
Gross profit growth  3.4% 41.4% 17.3% 28.5% 77.7%  
Employees  163 169 177 191 208  
Employee growth %  6.5% 3.7% 4.7% 7.9% 8.9%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,355 1,479 1,590 1,753 2,658  
Balance sheet change%  3.6% 9.1% 7.5% 10.3% 51.6%  
Added value  128.3 219.3 210.9 272.2 679.5  
Added value %  21.1% 28.0% 24.1% 24.7% 42.1%  
Investments  0 0 0 105 -40  

Net sales trend  3.0 4.0 5.0 5.0 5.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4
EBITDA %  21.1% 28.0% 24.1% 24.7% 42.1%  
EBIT %  21.1% 28.0% 24.1% 24.7% 42.1%  
EBIT to gross profit (%)  39.0% 47.2% 38.7% 38.8% 54.6%  
Net Earnings %  9.8% -15.2% 19.4% 10.3% 49.0%  
Profit before depreciation and extraordinary items %  9.8% -15.2% 19.4% 10.3% 49.0%  
Pre tax profit less extraordinaries %  21.1% 28.0% 24.1% 14.6% 49.5%  
ROA %  9.6% 15.5% 13.7% 15.9% 34.8%  
ROI %  9.6% 15.5% 13.7% 16.6% 37.1%  
ROE %  6.9% -15.1% 23.0% 13.8% 63.4%  

Solidity 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4
Equity ratio %  100.0% 100.0% 100.0% 48.7% 61.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 80.8% 63.3%  
Relative net indebtedness %  0.0% 0.0% 0.0% 20.8% -1.8%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% 35.6% -24.7%  
Gearing %  0.0% 0.0% 0.0% 88.9% 54.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 27.6% -3.6%  

Liquidity 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4
Quick Ratio  0.0 0.0 0.0 2.8 3.4  
Current Ratio  0.0 0.0 0.0 3.1 3.6  
Cash and cash equivalent  0.0 0.0 0.0 662.6 1,051.2  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4
Trade debtors turnover (days)  0.0 0.0 0.0 37.6 53.5  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 139.6% 155.4%  
Net working capital  0.0 0.0 0.0 805.5 864.4  
Net working capital %  0.0% 0.0% 0.0% 72.9% 53.6%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2022/4
2022
2023/4
2023
2024/4
Net sales / employee  4 5 5 6 8  
Added value / employee  1 1 1 1 3  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  1 1 1 1 3  
EBIT / employee  1 1 1 1 3  
Net earnings / employee  0 -1 1 1 4